Skip to content

Burden of Disease in Myasthenia Gravis

Questionnaire Survey on the Systematic Recording and Characterization of Quality of Life Limitations in Myasthenia Gravis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03979521
Acronym
Mya-BoD
Enrollment
1680
Registered
2019-06-07
Start date
2019-05-01
Completion date
2019-07-31
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Keywords

Myasthenia Gravis, Quality of life, Burden of disease, Social support

Brief summary

Questionnaire-based survey addressed to german patients with the chronic autoimmune muscle disease called myasthenia gravis regarding quality of life, socioeconomic impact, social support, course of disease, complications of therapy and psychological comorbidities.

Detailed description

Background: Myasthenia gravis is a rare, chronic, antibody-mediated autoimmune disease that results in muscular weakness. The patients suffer from symptoms such as visual disturbances (especially double vision), weakness in the arms and legs, chewing and swallowing disorders and respiratory disorders, as well as crisis-related worsening of ventilation. This is often accompanied by pronounced fatigue (physical) and mental fatigue (depression). Despite drug therapies that are on one hand symptomatic improving muscle strength, and on the other hand modulating the immune system, as well as specific procedures and drugs used in crises (plasmapheresis, immunoglobins) or refractory patients, patients are often severely limited, affecting everyday activities of self-care, family, social and professional life, thus affecting the mood and quality of life of patients. There is a lack of data measuring quality of life adequately. Aim: The aim of the data collection is to record the quality of life of myasthenia patients. By clinical information on the disease (including symptoms, course and therapy) and recording the social and occupational situation, the data should be contextualized. The following hypotheses are to be confirmed: Primary hypotheses * Myasthenia gravis affects the quality of life of patients comparable to neurological diseases such as multiple sclerosis * Patients are limited in their participation in their private and professional life * The severity of the disease is associated with the quality of life. Secondary hypotheses * Myasthenia is associated with income busses and other economic disadvantages of the night * Quality of life in myasthenia patients is related to fatigue and depression * Quality of life in myasthenia patients depends on different therapy methods * Myasthenia gravis has an impact on family planning and care for children. Methods: In cooperation with the German Myasthenia Gravis Society, a questionnaire prepared by the Charité will be sent to its members with a request for completion and an anonymous return. Similar projects have already been implemented in the past (response rate\> 30%). About 3,300 patients should be contacted. The returned questionnaires are then statistically evaluated and presented as part of a publication. For the evaluation of the hypotheses suitable descriptive, univariate analysis methods are used. Furthermore, with sufficient case numbers, multivariate analyzes (e.g., logistic regression) are also planned. The questionnaire contains general information and questions about: * Education and employment * Social situation * Social Support * Economic aspects * Symptoms and severity, course, treatment of myasthenia * Quality of life * Fatigue and depression

Interventions

None listed

Sponsors

NeuroCure Clinical Research Center, Charite, Berlin
CollaboratorOTHER
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Myasthenia Gravis * Age ≥18 years

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Questionnaire for self-completion by patients containing questions about general information, information on myasthenia, information socioeconomic situationdirectly after inclusion in the study
Hospital Anxiety and Depression Scale (HADS)directly after inclusion in the studyQuestionnaire for self-completion by patients to determine the levels of anxiety and depression
Mya Quality of Life 15 (Mya QoL15)directly after inclusion in the studyQuestionnaire for self-completion by patients for use as a measure of health outcome
Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF36)directly after inclusion in the studyQuestionnaire for self-completion by patients for patients health
Myasthenia gravis Activities of daily living (MG ADL)directly after inclusion in the studyQuestionnaire for self-completion by patients to determine symptom severity and limitations in activities of daily living

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026